

Références — Pariet

1. Monographie de produit du Pariet (rabéprazole sodique). Janssen-Ortho Inc. Toronto (Ontario), 31 mai 2002.
2. Welbanks L, rédacteur en chef. *Compendium of Pharmaceuticals and Specialties*, 37^e édition. Association des pharmaciens du Canada, 2002, Ottawa.
3. Breiter JR, Riff D, Humphries TJ, *et al.* Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease Results of a double-blind, randomized North American study. *Am J Gastroenterol* 2000;95(4): 936-42.
4. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the ewer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Données tirées des résultats d'essais cliniques aléatoires. *Clin Therapeut* 2001;23(7):998-1017.
5. Dekkers CPM, Beker JA, Thjodleifsson B, *et al.* Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. *Aliment Pharmacol Ther* 1999;13:179-86.
6. Dekkers CPM, Beker JA, Thjodleifsson B, *et al.* Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. *Aliment Pharmacol Ther* 1998;12:789-95.
7. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. *Aliment Pharmacol Thera* 2001;15:17289-36.
8. Erstad BL. Dyspepsia: Initial evaluation and treatment. *J Am Pharm Assoc* 002;42:460-
9. Farley A, Wruble LD, Humphries TJ, *et al.* Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial. *Am J Gastroenterol* 2000;95(8):1894-9.
10. Gray J (ed). *Therapeutic Choices*, 3rd édition. Association des pharmaciens du Canada, 2000; Ottawa.
11. Saltiel E, Stein T. Proton pump inhibitors in the treatment of GERD. *US Pharmacist* 2000;25(4) Supplement:3-13.
12. Tierney LM, McPhee SJ, Papadakis MA (eds). *Current Medical Diagnosis and Treatment*, 39th ed., 2000. Lange Medical Books/McGraw-Hill, Toronto.
13. Galmiche JP, Zerbib F, Ducrotte P, *et al.* Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. *Aliment Pharmacol Ther* 2110;15:1343-50.
14. Holtmann G, Bytzer P, Metz M, *et al.* A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2002;16:479-85.
15. Lanza F, Dev Bardhan K, Perdomo C, *et al.* Efficacy of rabeprazole once daily for acid-related disorders. *Dig Dis Sci* 2001;46(3):587-96.
16. New Pariet (rabeprazole sodium) Tablets Now Approved in Canada! [press release]. Janssen-Ortho Inc. 29 juillet 2002.
17. Thjodleifsson B, Beker JA, Dekkers C, *et al.* Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. *Digest Dis Sci* 2000;45(5):845-53.